Thus, our data revealed that the proportion of CD14+ monocytes begins to expand in the early stage of severe patients, and the CD14+/CD16+ monocyte ratios can serve as an appropriate early prognostic marker for severe COVID-19. This evidence concerns the gene FCGR3A and COVID-19.